BR112015020222A8 - composto de azetidiniloxifenilpirrolidina, seus usos, e composições farmacêuticas - Google Patents

composto de azetidiniloxifenilpirrolidina, seus usos, e composições farmacêuticas

Info

Publication number
BR112015020222A8
BR112015020222A8 BR112015020222A BR112015020222A BR112015020222A8 BR 112015020222 A8 BR112015020222 A8 BR 112015020222A8 BR 112015020222 A BR112015020222 A BR 112015020222A BR 112015020222 A BR112015020222 A BR 112015020222A BR 112015020222 A8 BR112015020222 A8 BR 112015020222A8
Authority
BR
Brazil
Prior art keywords
azetidinyloxyphenylpyrrolidine
compound
pharmaceutical compositions
compounds
formula
Prior art date
Application number
BR112015020222A
Other languages
English (en)
Other versions
BR112015020222A2 (pt
BR112015020222B1 (pt
Inventor
Huang Danwen
G Deng Gary
O Odingo Joshua
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112015020222A2 publication Critical patent/BR112015020222A2/pt
Publication of BR112015020222A8 publication Critical patent/BR112015020222A8/pt
Publication of BR112015020222B1 publication Critical patent/BR112015020222B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

resumo patente de invenção: "compostos de azetidiniloxifenilpirrolidina". a invenção refere-se a certos compostos de azetidiniloxifenilpirrolidina, particularmente compostos de fórmula i i em que r é hidrogênio ou metila, e composições farmacêuticas destes. a invenção refere-se adicionalmente a métodos para o uso de um composto de fórmula i para tratar bexiga hiperativa.
BR112015020222-5A 2013-03-13 2014-03-07 Azetidiniloxifenilpirrolidina, seus usos, e composições farmacêuticas BR112015020222B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361778546P 2013-03-13 2013-03-13
US61/778,546 2013-03-13
PCT/US2014/021474 WO2014159012A1 (en) 2013-03-13 2014-03-07 Azetidinyloxyphenylpyrrolidine compounds

Publications (3)

Publication Number Publication Date
BR112015020222A2 BR112015020222A2 (pt) 2017-07-18
BR112015020222A8 true BR112015020222A8 (pt) 2018-01-23
BR112015020222B1 BR112015020222B1 (pt) 2020-07-14

Family

ID=50382705

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015020222-5A BR112015020222B1 (pt) 2013-03-13 2014-03-07 Azetidiniloxifenilpirrolidina, seus usos, e composições farmacêuticas

Country Status (40)

Country Link
US (3) US9034864B2 (pt)
EP (2) EP2970222B1 (pt)
JP (2) JP6017708B2 (pt)
KR (2) KR101702797B1 (pt)
CN (2) CN109336865A (pt)
AP (1) AP3850A (pt)
AR (1) AR095015A1 (pt)
AU (1) AU2014241444B2 (pt)
BR (1) BR112015020222B1 (pt)
CA (1) CA2899806C (pt)
CL (1) CL2015002113A1 (pt)
CR (1) CR20150417A (pt)
CY (1) CY1120142T1 (pt)
DK (1) DK2970222T3 (pt)
DO (1) DOP2015000176A (pt)
EA (1) EA026631B1 (pt)
ES (1) ES2616470T3 (pt)
HK (1) HK1212695A1 (pt)
HR (1) HRP20170080T1 (pt)
HU (1) HUE032235T2 (pt)
IL (1) IL240904B (pt)
JO (1) JO3264B1 (pt)
LT (1) LT2970222T (pt)
MA (1) MA38410B1 (pt)
ME (1) ME02592B (pt)
MX (1) MX2015012579A (pt)
MY (1) MY180006A (pt)
NZ (1) NZ710481A (pt)
PE (1) PE20151669A1 (pt)
PH (1) PH12015502032A1 (pt)
PL (1) PL2970222T3 (pt)
PT (1) PT2970222T (pt)
RS (1) RS55594B1 (pt)
SG (2) SG10201609717YA (pt)
SI (1) SI2970222T1 (pt)
TN (1) TN2015000384A1 (pt)
TW (1) TWI617553B (pt)
UA (1) UA115583C2 (pt)
WO (1) WO2014159012A1 (pt)
ZA (1) ZA201505417B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI617553B (zh) * 2013-03-13 2018-03-11 美國禮來大藥廠 吖丁啶基氧苯基吡咯啶化合物
WO2016033776A1 (en) * 2014-09-04 2016-03-10 Eli Lilly And Company Crystalline (2s) -3- [ (3s, 4s) -3- [ (1r) -1-hydroxyethyl] -4- (4-methoxy-3- { [1- (5-methylpyridin-2-yl) azetidin-3-yl] oxy} phenyl) -3-methylpyrrolidin-1-yl] -3-oxopropane-1, 2-diol
TW201625591A (zh) * 2014-09-12 2016-07-16 美國禮來大藥廠 吖丁啶基氧苯基吡咯啶化合物
EP3901146A4 (en) * 2018-12-18 2022-01-19 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company PHENYLPYRROLIDINE COMPOUND AND USE THEREOF
CN111333625B (zh) * 2018-12-18 2022-10-18 武汉人福创新药物研发中心有限公司 苯基吡咯烷类化合物及其用途
CN111333637B (zh) * 2018-12-18 2022-07-29 武汉人福创新药物研发中心有限公司 苯基吡咯烷类衍生物及其制备方法
CN112409333A (zh) * 2019-08-23 2021-02-26 湖北生物医药产业技术研究院有限公司 苯基吡咯烷类化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
JPH07300455A (ja) * 1994-03-08 1995-11-14 Mitsubishi Chem Corp 3−フェニルピロリジン誘導体
DE19601938A1 (de) * 1996-01-12 1997-07-17 Schering Ag Neue Phosphodiesteraseinhibitoren
US6376489B1 (en) * 1999-12-23 2002-04-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6258833B1 (en) 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
PL365443A1 (en) * 2001-01-31 2005-01-10 Pfizer Products Inc. Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
WO2007039075A2 (en) 2005-09-29 2007-04-12 Bayer Healthcare Ag Pde inhibitors and combinations thereof for the treatment of urological disorders
TW201206440A (en) 2010-04-28 2012-02-16 Astellas Pharma Inc Prophylactic or therapeutic agent for diseases associated with pains in urinary organs
EP2569302A1 (en) 2010-05-13 2013-03-20 Amgen, Inc Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
TWI617553B (zh) * 2013-03-13 2018-03-11 美國禮來大藥廠 吖丁啶基氧苯基吡咯啶化合物

Also Published As

Publication number Publication date
MA38410A1 (fr) 2016-02-29
RS55594B1 (sr) 2017-06-30
CN105051034B (zh) 2019-05-21
EA201591498A1 (ru) 2015-12-30
JP2016510759A (ja) 2016-04-11
PL2970222T3 (pl) 2017-06-30
BR112015020222A2 (pt) 2017-07-18
KR20150119077A (ko) 2015-10-23
UA115583C2 (uk) 2017-11-27
AP2015008699A0 (en) 2015-09-30
MY180006A (en) 2020-11-19
WO2014159012A9 (en) 2014-12-18
EP2970222B1 (en) 2016-12-21
TW201522327A (zh) 2015-06-16
NZ710481A (en) 2020-08-28
AU2014241444A1 (en) 2015-08-06
EA026631B1 (ru) 2017-04-28
EP3168216A1 (en) 2017-05-17
ZA201505417B (en) 2022-09-28
CN109336865A (zh) 2019-02-15
CL2015002113A1 (es) 2016-01-15
CA2899806C (en) 2017-07-18
CA2899806A1 (en) 2014-10-02
KR20170013411A (ko) 2017-02-06
AP3850A (en) 2016-09-30
AR095015A1 (es) 2015-09-16
US9034864B2 (en) 2015-05-19
PH12015502032A1 (en) 2016-01-18
SG11201507501YA (en) 2015-10-29
TWI617553B (zh) 2018-03-11
ES2616470T3 (es) 2017-06-13
JP6204557B2 (ja) 2017-09-27
AU2014241444B2 (en) 2016-04-07
DOP2015000176A (es) 2015-11-15
US20160122322A1 (en) 2016-05-05
KR101745304B1 (ko) 2017-06-08
HUE032235T2 (en) 2017-09-28
IL240904B (en) 2019-02-28
TN2015000384A1 (en) 2017-01-03
WO2014159012A1 (en) 2014-10-02
SG10201609717YA (en) 2017-01-27
JP2016216517A (ja) 2016-12-22
JP6017708B2 (ja) 2016-11-02
US9604967B2 (en) 2017-03-28
CR20150417A (es) 2015-09-16
IL240904A0 (en) 2015-10-29
SI2970222T1 (sl) 2017-02-28
LT2970222T (lt) 2017-03-27
ME02592B (me) 2017-06-20
CN105051034A (zh) 2015-11-11
US9266859B2 (en) 2016-02-23
US20140275002A1 (en) 2014-09-18
HRP20170080T1 (hr) 2017-03-10
HK1212695A1 (zh) 2016-06-17
PE20151669A1 (es) 2015-11-12
MA38410B1 (fr) 2016-09-30
DK2970222T3 (en) 2017-02-27
EP2970222A1 (en) 2016-01-20
US20150133423A1 (en) 2015-05-14
KR101702797B1 (ko) 2017-02-06
MX2015012579A (es) 2016-01-20
PT2970222T (pt) 2017-02-08
JO3264B1 (ar) 2018-09-16
BR112015020222B1 (pt) 2020-07-14
CY1120142T1 (el) 2018-12-12

Similar Documents

Publication Publication Date Title
BR112015018738A8 (pt) compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica
BR112015020222A8 (pt) composto de azetidiniloxifenilpirrolidina, seus usos, e composições farmacêuticas
BR112017002053A2 (pt) composto de acordo com a fórmula (i), composição farmacêutica, e usos de um composto
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
ECSP16005566A (es) Sulfonamidas como moduladores de canales de sodio
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
DK2970216T3 (da) Biarylamidforbindelser som kinaseinhibitorer
BR112017002214A2 (pt) composto de fórmula (i), composição farmacêutica e usos de um composto
BR112015021352A2 (pt) composições antimicrobianas
BR112015024530A8 (pt) compostos derivados de naftiridina úteis como antagonistas de integrina alfa-v-beta-6, composição farmacêutica, e, uso de um composto
BR112015019276A2 (pt) compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios
BR112016007427A2 (pt) compostos de pirazol-amida e usos dos mesmos
BR112015026967A8 (pt) fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica
BR112012024822B8 (pt) Composto, uso de um composto e composição farmacêutica
BR112015012825A2 (pt) piridopirazinas substituídas como inibidores de syk
BR112014007078A2 (pt) composição de controle de doença de plantas e seu uso
BR112015004523A2 (pt) compostos de tetraciclina
BR112015024075A2 (pt) compostos de piridinilpirazoloquinolina
MX2015012318A (es) Formas de estado solido de un derivado de quinazolina y su uso como un inhibidor de braf.
BR112016008704A8 (pt) derivados de indol-urea glucopiranosil-substituídos, composições farmacêuticas, e seus usos
BR112015030589A8 (pt) formas polimórficas de fosfato de icotinibe, composição farmacêutica compreendendo as referidas formas e usos das mesmas
BR112017021589A2 (pt) métodos para o tratamento de transtornos cardiovasculares
BR112015022970A2 (pt) composição farmacêutica de cloridrato de s-cetamina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/03/2014, OBSERVADAS AS CONDICOES LEGAIS.